Investment Thesis
Actinium Pharmaceuticals is a pre-commercial biotech company with minimal revenue ($90K) and severe operating losses (-$5.9M per period). While the $42.1M cash position provides near-term runway, the combination of negative free cash flow, thin stockholders' equity ($2.3M), and complete dependence on unproven commercialization creates existential risk. At current burn rates, cash runway is limited to approximately 7 quarters without additional capital.
Strengths
- Strong cash position of $42.1M provides operational runway
- Excellent liquidity with current ratio of 5.89x
- Low leverage with debt-to-equity ratio of 0.39x
Risks
- Pre-commercial status with virtually no revenue generation ($90K)
- Significant operating cash burn of $5.9M per period
- Stockholders' equity of only $2.3M creates minimal equity cushion against further losses
- Negative free cash flow indicating unsustainable cash consumption
- Limited cash runway at current burn rate (~1.75 years) without additional capital raise
- Pharma company with no proven product commercialization track record
Key Metrics to Watch
- Revenue growth trajectory and product commercialization milestones
- Quarterly cash burn rate and remaining months of runway
- Changes in stockholders' equity and capital adequacy
- Clinical trial progress and regulatory approval timelines
Financial Metrics
Revenue
90.0K
Net Income
-5.5M
EPS (Diluted)
$-0.18
Free Cash Flow
-5.9M
Total Assets
45.4M
Cash
42.1M
Profitability Ratios
Gross Margin
0.0%
Operating Margin
-6,558.9%
Net Margin
-6,135.6%
ROE
-239.7%
ROA
-12.2%
FCF Margin
-6,524.4%
Balance Sheet & Liquidity
Current Ratio
5.89x
Quick Ratio
5.89x
Debt/Equity
0.39x
Debt/Assets
94.9%
Interest Coverage
-1,178.95x
Long-term Debt
900.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:16:19.792148 |
Data as of: 2026-03-31 |
Powered by Claude AI